酒精间隔消融术治疗肥厚型梗阻性心肌病
Alcohol Septal Ablation for the Treatment of Hypertrophic Obstructive Cardiomyopathy.
作者信息
O'Mahony Constantinos, Mohiddin Saidi A, Knight Charles
机构信息
The Heart Muscle Disease Clinic, London Chest Hospital, London, UK.
出版信息
Interv Cardiol. 2014 Apr;9(2):108-114. doi: 10.15420/icr.2011.9.2.108.
Abstract
Hypertrophic cardiomyopathy (HCM) is an inherited myocardial disorder characterised by left ventricular hypertrophy. A subgroup of patients develops limiting symptoms in association with left ventricular outflow tract obstruction (LVOTO). Current international guidelines recommend that symptomatic patients are initially treated by alleviating exacerbating factors and negatively inotropic medication. Drug-refractory symptoms require a comprehensive evaluation of the mechanism of LVOTO and review by a multidisciplinary team to consider the relative merits of myectomy, alcohol septal ablation (ASA) and pacing. This article provides a brief overview of HCM and the pathophysiology of LVOTO, and reviews the use of ASA in patients with drug-refractory symptoms secondary to LVOTO.
摘要
肥厚型心肌病（HCM）是一种以左心室肥厚为特征的遗传性心肌疾病。一部分患者会出现与左心室流出道梗阻（LVOTO）相关的限制性症状。目前的国际指南建议，有症状的患者最初应通过缓解加重因素和使用负性肌力药物进行治疗。药物难治性症状需要对LVOTO的机制进行全面评估，并由多学科团队进行审查，以考虑肌切除术、酒精间隔消融术（ASA）和起搏的相对优缺点。本文简要概述了HCM和LVOTO的病理生理学，并综述了ASA在LVOTO继发药物难治性症状患者中的应用。
相似文献
1
Alcohol Septal Ablation for the Treatment of Hypertrophic Obstructive Cardiomyopathy.酒精间隔消融术治疗肥厚型梗阻性心肌病
Interv Cardiol. 2014 Apr;9(2):108-114. doi: 10.15420/icr.2011.9.2.108.
2
Multidisciplinary evaluation and management of obstructive hypertrophic cardiomyopathy in 2020: Towards the HCM Heart Team.2020年梗阻性肥厚型心肌病的多学科评估与管理：迈向肥厚型心肌病心脏团队
Int J Cardiol. 2020 Apr 1;304:86-92. doi: 10.1016/j.ijcard.2020.01.021. Epub 2020 Jan 11.
3
Current state of the roles of alcohol septal ablation and surgical myectomy in the treatment of hypertrophic obstructive cardiomyopathy.酒精间隔消融术和外科心肌切除术在肥厚性梗阻性心肌病治疗中的作用现状
Cardiovasc Diagn Ther. 2020 Feb;10(1):36-44. doi: 10.21037/cdt.2019.07.02.
4
Septal Ablation Versus Surgical Myomectomy for Hypertrophic Obstructive Cardiomyopathy.肥厚性梗阻性心肌病的间隔消融术与外科肌瘤切除术对比
Curr Cardiol Rep. 2021 Oct 1;23(11):165. doi: 10.1007/s11886-021-01600-5.
5
Alcohol septal ablation markedly reduces energy loss in hypertrophic cardiomyopathy with left ventricular outflow tract obstruction: A four-dimensional flow cardiac magnetic resonance study.酒精间隔消融术显著降低肥厚型心肌病伴左心室流出道梗阻的能量损失：一项四维血流心脏磁共振研究。
Int J Cardiol Heart Vasc. 2021 Oct 9;37:100886. doi: 10.1016/j.ijcha.2021.100886. eCollection 2021 Dec.
6
A meta analysis of current status of alcohol septal ablation and surgical myectomy for obstructive hypertrophic cardiomyopathy.酒精间隔消融术与外科室间隔切除术治疗梗阻性肥厚型心肌病现状的荟萃分析
Catheter Cardiovasc Interv. 2016 Jul;88(1):107-15. doi: 10.1002/ccd.26293. Epub 2015 Nov 3.
7
From 100 to 0: Endocardial Radiofrequency Ablation of Septal Hypertrophy for Management of Hypertrophic Cardiomyopathy.从100到0：经心内膜射频消融肥厚间隔治疗肥厚型心肌病
JACC Case Rep. 2020 Jul 15;2(8):1173-1177. doi: 10.1016/j.jaccas.2020.05.042. eCollection 2020 Jul.
8
Therapeutic management of hypertrophic obstructive cardiomyopathy: alcohol septal ablation or surgical myomectomy?肥厚性梗阻性心肌病的治疗管理：酒精间隔消融术还是外科肌瘤切除术？
Expert Rev Cardiovasc Ther. 2014 Sep;12(9):1041-4. doi: 10.1586/14779072.2014.942287. Epub 2014 Jul 21.
9
Comparison of surgical septal myectomy and alcohol septal ablation with cardiac magnetic resonance imaging in patients with hypertrophic obstructive cardiomyopathy.肥厚型梗阻性心肌病患者外科室间隔心肌切除术与酒精室间隔消融术的心脏磁共振成像比较
J Am Coll Cardiol. 2007 Jan 23;49(3):350-7. doi: 10.1016/j.jacc.2006.08.055. Epub 2007 Jan 4.
10
Glue septal ablation: A promising alternative to alcohol septal ablation.胶水间隔消融术：酒精间隔消融术的一种有前景的替代方法。
JRSM Cardiovasc Dis. 2016 Mar 3;5:2048004016636313. doi: 10.1177/2048004016636313. eCollection 2016 Jan-Dec.
引用本文的文献
1
Integrative Approaches in the Management of Hypertrophic Cardiomyopathy: A Comprehensive Review of Current Therapeutic Modalities.肥厚型心肌病管理中的综合方法：当前治疗方式的全面综述
Biomedicines. 2025 May 21;13(5):1256. doi: 10.3390/biomedicines13051256.
2
A modified endocardial radiofrequency ablation approach for hypertrophic obstructive cardiomyopathy guided by transthoracic echocardiography: a case series.经胸超声心动图引导下改良心内膜射频消融术治疗肥厚型梗阻性心肌病：病例系列
Ann Transl Med. 2021 Jun;9(12):1006. doi: 10.21037/atm-21-2783.
本文引用的文献
1
A novel clinical risk prediction model for sudden cardiac death in hypertrophic cardiomyopathy (HCM risk-SCD).肥厚型心肌病患者心脏性猝死的新型临床风险预测模型（HCM risk-SCD）。
Eur Heart J. 2014 Aug 7;35(30):2010-20. doi: 10.1093/eurheartj/eht439. Epub 2013 Oct 14.
2
Clinical characteristics and natural history of hypertrophic cardiomyopathy with midventricular obstruction.伴有室间隔中部梗阻的肥厚型心肌病的临床特征和自然病史。
Circ J. 2013;77(9):2366-74. doi: 10.1253/circj.cj-12-1561. Epub 2013 May 31.
3
Treatment of obstructive hypertrophic cardiomyopathy symptoms and gradient resistant to first-line therapy with β-blockade or verapamil.治疗梗阻性肥厚型心肌病症状和对一线治疗（β受体阻滞剂或维拉帕米）有抵抗的梯度。
Circ Heart Fail. 2013 Jul;6(4):694-702. doi: 10.1161/CIRCHEARTFAILURE.112.000122. Epub 2013 May 23.
4
Diagnostic work-up in cardiomyopathies: bridging the gap between clinical phenotypes and final diagnosis. A position statement from the ESC Working Group on Myocardial and Pericardial Diseases.心肌病的诊断检查：弥合临床表型与最终诊断之间的差距。ESC 心肌和心包疾病工作组的立场声明。
Eur Heart J. 2013 May;34(19):1448-58. doi: 10.1093/eurheartj/ehs397. Epub 2012 Dec 4.
5
Sarcomeric hypertrophic cardiomyopathy: genetic profile in a Portuguese population.肌节性肥厚型心肌病：葡萄牙人群的基因图谱
Rev Port Cardiol. 2012 Sep;31(9):577-87. doi: 10.1016/j.repc.2011.12.020. Epub 2012 Aug 2.
6
Pacing for drug-refractory or drug-intolerant hypertrophic cardiomyopathy.药物难治性或药物不耐受性肥厚型心肌病的起搏治疗
Cochrane Database Syst Rev. 2012 May 16;2012(5):CD008523. doi: 10.1002/14651858.CD008523.pub2.
7
Long-term outcomes in hypertrophic cardiomyopathy caused by mutations in the cardiac troponin T gene.心肌肌钙蛋白T基因突变所致肥厚型心肌病的长期预后
Circ Cardiovasc Genet. 2012 Feb 1;5(1):10-7. doi: 10.1161/CIRCGENETICS.111.959973. Epub 2011 Dec 5.
8
2011 ACCF/AHA Guideline for the Diagnosis and Treatment of Hypertrophic Cardiomyopathy: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Developed in collaboration with the American Association for Thoracic Surgery, American Society of Echocardiography, American Society of Nuclear Cardiology, Heart Failure Society of America, Heart Rhythm Society, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons.2011年美国心脏病学会基金会/美国心脏协会肥厚型心肌病诊断和治疗指南：美国心脏病学会基金会/美国心脏协会实践指南工作组报告。与美国胸外科协会、美国超声心动图学会、美国核心脏病学会、美国心力衰竭学会、心律学会、心血管造影和介入学会以及胸外科医师学会合作制定。
J Am Coll Cardiol. 2011 Dec 13;58(25):e212-60. doi: 10.1016/j.jacc.2011.06.011. Epub 2011 Nov 8.
9
Transradial approach and subclavian wired temporary pacemaker to increase safety of alcohol septal ablation for treatment of obstructive hypertrophic cardiomyopathy: the TRASA trial.经桡动脉入路联合锁骨下有线临时起搏器增加酒精室间隔消融术治疗梗阻性肥厚型心肌病的安全性：TRASA 试验。
Arch Cardiovasc Dis. 2011 Aug;104(8-9):444-9. doi: 10.1016/j.acvd.2011.05.006. Epub 2011 Aug 27.
10
Clinical implications of midventricular obstruction in patients with hypertrophic cardiomyopathy.肥厚型心肌病患者中段室间隔梗阻的临床意义。
J Am Coll Cardiol. 2011 Jun 7;57(23):2346-55. doi: 10.1016/j.jacc.2011.02.033.
Zotero 插件